Search results
Results From The WOW.Com Content Network
Covaxin (development name, BBV152) is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.
Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company based in Hyderabad, which is engaged in drug discovery, drug development, and the manufacture of vaccines, biotherapeutics, pharmaceuticals and healthcare products.
Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Ocugen said that the studies on its effectiveness against the Omicron variant are ongoing. The results will be ...
Bharat Biotech is the first in the world to find a vaccine for the Zika virus. [9] [10] Bharat Biotech has delivered over 4 billion vaccines in 123 countries. [4] The vaccine against COVID-19 developed by Bharat Biotech, named Covaxin, was endorsed by the Indian government with an active push by theā Indian Prime Minister Narendra Modi. [11]
India's Bharat Biotech is in the process of filing regulatory documents for approval of its COVID-19 vaccine, COVAXIN, in more than 40 countries, the company told Reuters late on Wednesday.
A vial of Covaxin, India's first indigenous COVID-19 vaccine by Bharat Biotech. On 2 January 2021, Covaxin India's first COVID-19 vaccine, developed by Bharat Biotech in association with the Indian Council of Medical Research and National Institute of Virology received approval from the Drug Controller General of India for its emergency or ...
Covaxin or BBV152 (Bharat Biotech) Released for emergency use [22] 81% India Inactivated virus Phase 3 closed; 25,800 participants Common: pain at the injection site, headache, fatigue and fever [23] [24] [25] Note 1: the vaccine was released in India before data from phase 2 trials
Bharat Biotech is a pioneering biotechnology company known for its world-class research and development and manufacturing capabilities. As part of the collaboration, the companies will co-develop and commercialize AV0328, a synthetic vaccine targeting poly N-acetyl glucosamine (PNAG), in India and other licensed territories.